Ascletis Pharma, Inc. (HK:1672)
:1672
Want to see HK:1672 full AI Analyst Report?
Top Page
Ascletis Pharma, Inc.
(1672)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$16.00
▼(-13.42% Downside)
Action:Reiterated
Date:05/04/26
The score is primarily constrained by weak financial performance—collapsing revenue, very negative profitability, and sustained high cash burn—despite low leverage. Technicals are mixed (positive long-term trend vs weak short-term momentum), while valuation is not supportive due to negative earnings and no dividend yield data.
Positive Factors
Low leverage / strong balance sheet
Very low debt relative to equity provides a durable solvency buffer for a biotech with long development cycles. This reduces near-term refinancing risk, preserves optionality to fund trials or partnerships, and gives time to execute strategic remedies if cash burn persists.
Negative Factors
Severe revenue collapse
The dramatic multi-year revenue decline materially erodes the business base and impairs the company’s ability to cover fixed costs. Without a sustained top-line recovery, product commercialization economics and long-term viability hinge on new launches or sizeable partner financings.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low debt relative to equity provides a durable solvency buffer for a biotech with long development cycles. This reduces near-term refinancing risk, preserves optionality to fund trials or partnerships, and gives time to execute strategic remedies if cash burn persists.
Read all positive factors
Ascletis Pharma, Inc. (1672) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$15.76B
Dividend YieldN/A
Average Volume (3M)8.30M
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth57.92%
EPS Growth-23.76%
CountryHK
Employees231
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.37
Shares Outstanding1,068,455,100
10 Day Avg. Volume6,104,199
30 Day Avg. Volume8,303,348
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)5.14
Price to Sales (P/S)4905.97
P/FCF Ratio-30.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$20.17Price Target Upside9.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.9
Revenue Forecast (FY)HK$1.29B
Ascletis Pharma, Inc. Business Overview & Revenue Model
Company Description
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic ...
How the Company Makes Money
Ascletis makes money primarily by (1) selling its commercial pharmaceutical products (i.e., recognized revenue from marketed drugs through distribution to hospitals, pharmacies, and other healthcare channels, depending on the market), and (2) gene...
Ascletis Pharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.03M | 1.28M | 56.60M | 54.09M | 76.88M |
| Gross Profit | 527.00K | 735.00K | 25.99M | -24.69M | 39.17M |
| EBITDA | -471.65M | -390.45M | -126.09M | -284.50M | -169.35M |
| Net Income | -359.88M | -300.94M | -144.72M | -314.84M | -199.02M |
Balance Sheet | |||||
| Total Assets | 2.07B | 2.12B | 2.49B | 2.66B | 2.83B |
| Cash, Cash Equivalents and Short-Term Investments | 1.90B | 1.95B | 2.30B | 2.48B | 2.50B |
| Total Debt | 5.16M | 7.63M | 8.42M | 4.24M | 2.75M |
| Total Liabilities | 129.93M | 158.41M | 148.94M | 117.16M | 100.89M |
| Stockholders Equity | 1.94B | 1.97B | 2.34B | 2.54B | 2.73B |
Cash Flow | |||||
| Free Cash Flow | -330.83M | -343.73M | -163.32M | -156.85M | -154.13M |
| Operating Cash Flow | -329.23M | -341.58M | -144.16M | -142.45M | -146.93M |
| Investing Cash Flow | 565.97M | 978.91M | 149.84M | -1.30B | -274.49M |
| Financing Cash Flow | 336.29M | -103.51M | -81.50M | -1.42M | -31.10M |
Ascletis Pharma, Inc. Technical Analysis
Neutral
18.48
Price Trends
16.45
Negative
15.20
Positive
13.71
Positive
Market Momentum
-0.16
Positive
36.90
Neutral
25.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1672, the sentiment is Neutral. The current price of 18.48 is above the 20-day moving average (MA) of 17.11, above the 50-day MA of 16.45, and above the 200-day MA of 13.71, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 36.90 is Neutral, neither overbought nor oversold. The STOCH value of 25.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1672.
Ascletis Pharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | HK$17.83B | 50.10 | 10.12% | ― | 110.05% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$39.90B | -256.36 | -10.78% | ― | 34.19% | 47.97% | |
50 Neutral | HK$12.15B | -15.04 | -64.19% | ― | -33.37% | -344.90% | |
47 Neutral | HK$15.76B | -27.65 | -18.69% | ― | 57.92% | -23.76% | |
47 Neutral | HK$16.24B | -9.51 | -24.29% | ― | 8.50% | 35.24% | |
44 Neutral | HK$14.37B | -6.78 | -123.74% | ― | -41.32% | -159.81% |
* Healthcare Sector Average
HK:1672
Ascletis Pharma, Inc.
14.85
7.85
112.14%
HK:9688
Zai Lab Ltd
14.35
-10.95
-43.28%
HK:9969
InnoCare Pharma Ltd.
11.93
0.95
8.65%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
23.16
6.22
36.72%
HK:2616
CStone Pharmaceuticals
7.70
4.04
110.38%
HK:6855
Ascentage Pharma Group International
38.80
-10.40
-21.14%
Ascletis Pharma, Inc. Corporate Events
Ascletis to Unveil Obesity and Metabolic Drug Data at ADA 2026
Apr 30, 2026
Ascletis Pharma Inc. announced that it will present new data from multiple obesity and metabolic drug candidates at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans. The presentations will showcase preclinical data...
Ascletis Completes U.S. Phase II Enrollment for Oral GLP-1 Diabetes Drug ASC30
Apr 27, 2026
Ascletis Pharma has completed enrollment in a 13-week U.S. Phase II trial of ASC30, its once-daily oral small molecule GLP-1 receptor agonist, in 100 patients with type 2 diabetes mellitus. The randomized, double-blind, placebo-controlled study wi...
Ascletis Advances Fixed-Dose Oral Obesity Pill Toward U.S. FDA IND in 2026
Apr 7, 2026
Ascletis Pharma has selected ASC30_39 FDC, a fixed-dose oral tablet combining its once-daily GLP-1 receptor agonist ASC30 and amylin-selective receptor agonist ASC39, as a new clinical candidate for obesity. The company plans to submit an Investig...
Ascletis Deepens R&D Push in Obesity Drugs as 2025 Loss Widens
Mar 31, 2026
Ascletis Pharma reported a modest 5.2% increase in total income to RMB127.4 million for 2025 but saw its net loss widen by 19.6% to RMB359.9 million, driven mainly by a 35.3% surge in research and development spending to RMB409.1 million, while ad...
Ascletis Pharma Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
Mar 18, 2026
Ascletis Pharma Inc. has announced that its board of directors will convene a meeting on March 31, 2026 to review and approve the annual results for the year ended December 31, 2025. The board will also consider the publication of these results an...
Ascletis Advances Oral Amylin Agonist ASC39 Toward U.S. IND for Obesity
Mar 17, 2026
Ascletis Pharma has advanced ASC39, an in-house discovered oral small molecule amylin receptor agonist, as a clinical candidate for obesity, highlighting its comparable receptor selectivity and potency to peptide analog eloralintide in cAMP activa...
Ascletis Posts Positive U.S. Phase II Data for Monthly GLP-1 Obesity Drug ASC30
Mar 10, 2026
Ascletis Pharma reported positive topline data from a 24-week U.S. Phase II trial of its ultra-long-acting subcutaneous depot formulation of small molecule GLP-1 receptor agonist ASC30 in obese or overweight patients. The A1 formulation delivered ...
Ascletis Advances Oral Amylin Obesity Drug ASC36 Toward U.S. Clinical Trials
Feb 10, 2026
Ascletis Pharma has selected ASC36, its first oral amylin receptor peptide agonist, for clinical development, aiming to treat obesity with a once-daily tablet built on its POTENT oral peptide transport technology. The company plans to file an Inve...
Ascletis Raises HK$835 Million to Fund Global Phase III Obesity Drug Trials
Feb 10, 2026
Ascletis Pharma Inc. has completed a placing of 69,256,000 new shares under its general mandate at HK$12.18 per share, raising gross proceeds of about HK$843.5 million and net proceeds of approximately HK$835.2 million. The new shares, placed with...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.